Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
22
RNAZ Quote, Financials, Valuation and Earnings
Last price:
$8.59
Seasonality move
:
-30.19%
Day range:
$8.45 - $8.78
52-week range:
$6.15 - $468.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.92x
Volume:
10.6K
Avg. volume:
13K
1-year change:
-96.84%
Market cap:
$7M
Revenue:
--
EPS (TTM):
-$242.08
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, TransCode Therapeutics, Inc. has 3229.37% upside to fair value with a price target of $10.00 per share.
RNAZ vs. S&P 500
-
Over the past 5 trading days, TransCode Therapeutics, Inc. has underperformed the S&P 500 by -8.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
TransCode Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TransCode Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter TransCode Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
TransCode Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter TransCode Therapeutics, Inc. reported earnings per share of -$5.82.
Enterprise value:
4.2M
EV / Invested capital:
2.93x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.29x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$192.3K
Return On Assets:
-357.8%
Net Income Margin (TTM):
--
Return On Equity:
-775.26%
Return On Invested Capital:
-766.9%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$406.1K | -$552.2K | -$192.3K | -$127.5K | -$4.8K | |
| Operating Income | -$20.9M | -$14.6M | -$17M | -$2.2M | -$4.6M | |
| EBITDA | -$20.5M | -$14.1M | -$16.9M | -$2M | -$4.6M | |
| Diluted EPS | -$25,834.25 | -$265.83 | -$242.08 | -$5.22 | -$5.82 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $25.2M | $11.6M | $9.4M | $3.6M | $4.8M | |
| Total Assets | $25.4M | $12M | $10.2M | $3.9M | $5.2M | |
| Current Liabilities | $2.2M | $3.8M | $5.6M | $2.3M | $3M | |
| Total Liabilities | $2.2M | $3.8M | $5.8M | $2.3M | $3.8M | |
| Total Equity | $23.2M | $8.2M | $4.4M | $1.7M | $1.4M | |
| Total Debt | -- | -- | $189.8K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.2M | -$15.9M | -$14.5M | -$3.9M | -$4.1M | |
| Cash From Investing | -$63.8K | -$21.3K | -$500 | -$12.9K | -- | |
| Cash From Financing | $14.9M | $10.3M | $15.5M | $2.4M | -$455.7K | |
| Free Cash Flow | -$16.3M | -$15.9M | -$14.5M | -$3.9M | -$4.1M | |
RNAZ
Sector
Market Cap
$7M
$28.4M
Price % of 52-Week High
1.8%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-177.34%
-1.32%
1-Year Price Total Return
-96.68%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.00
200-day SMA
Sell
Level
$16.87
Bollinger Bands (100)
Sell
Level
9.26 - 12.54
Chaikin Money Flow
Sell
Level
-17.4M
20-day SMA
Sell
Level
$9.02
Relative Strength Index (RSI14)
Sell
Level
37.76
ADX Line
Sell
Level
20.6
Williams %R
Buy
Level
-82.9476
50-day SMA
Sell
Level
$11.02
MACD (12, 26)
Sell
Level
-0.61
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
24.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-18.2803)
Sell
CA Score
(Annual)
Level (-14.229)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (16.1461)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, RNAZ has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RNAZ average analyst price target in the past 3 months is $10.00.
-
Where Will TransCode Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that TransCode Therapeutics, Inc. share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About TransCode Therapeutics, Inc.?
Analysts are divided on their view about TransCode Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TransCode Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is TransCode Therapeutics, Inc.'s Price Target?
The price target for TransCode Therapeutics, Inc. over the next 1-year time period is forecast to be $10.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RNAZ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TransCode Therapeutics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of RNAZ?
You can purchase shares of TransCode Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TransCode Therapeutics, Inc. shares.
-
What Is The TransCode Therapeutics, Inc. Share Price Today?
TransCode Therapeutics, Inc. was last trading at $8.59 per share. This represents the most recent stock quote for TransCode Therapeutics, Inc.. Yesterday, TransCode Therapeutics, Inc. closed at $8.64 per share.
-
How To Buy TransCode Therapeutics, Inc. Stock Online?
In order to purchase TransCode Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RNAZ Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RNAZ
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
4.92x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
RNAZ
Sector
Revenue growth
--
4.85%
Earnings growth
-11.66%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.33
-$0.20
Profitability
RNAZ
Sector
Profitability FY 2024
-$534.9K
$3.6M
Return on invested capital
-766.9%
-30.98%
Return on assets
-357.8%
-27.62%
Return on equity
-775.26%
-36.69%
Earnings Date
Last Earnings Date
Dec
5
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
RNAZ
Sector
Total cash
$2.8M
$27.2M
Short term investments
--
$25.7M
Total assets
$7.3M
$79.9M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
